Gsa Capital Partners LLP Verastem, Inc. Transaction History

Gsa Capital Partners LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.92 - $11.16 $59,454 - $721,203	64,624 New	64,624 $55,000
Q3 2020 Nov 06, 2020	SELL	$1.11 - $1.68 $11,748 - $17,781	-10,584 Closed	0 $0
Q2 2020 Aug 11, 2020	BUY	$1.69 - $4.2 $17,886 - $44,452	10,584 New	10,584 $18,000
Q4 2019 Feb 12, 2020	SELL	$0.86 - $1.44 $17,296 - $28,961	-20,112 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$1.21 - $1.59 $95,523 - $125,522	-78,945 Reduced 79.7%	20,112 $24,000
Q2 2019 Aug 06, 2019	BUY	$1.25 - $3.14 $107,358 - $269,685	85,887 Added 652.14%	99,057 $150,000
Q1 2019 May 15, 2019	SELL	$2.79 - $4.09 $14,463 - $21,202	-5,184 Reduced 28.24%	13,170 $39,000
Q4 2018 Feb 12, 2019	BUY	$3.23 - $7.01 $59,283 - $128,661	18,354 New	18,354 $62,000
Q3 2018 Nov 13, 2018	SELL	$6.86 - $9.97 $751,540 - $1.09 Million	-109,554 Closed	0 $0
Q2 2018 Aug 09, 2018	SELL	$2.88 - $8.67 $488,448 - $1.47 Million	-169,600 Reduced 60.75%	109,554 $754,000
Q1 2018 May 11, 2018	BUY	$2.92 - $3.81 $330,106 - $430,720	113,050 Added 68.06%	279,154 $832,000
Q4 2017 Feb 14, 2018	BUY	$2.99 - $4.85 $496,650 - $805,604	166,104	166,104 $510,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.09B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.